Pharmaxis Ltd Price (PXS.AX)

Stock Price

Low: Year Low
High: Year High

Market Cap

Fetching Data...

Enterprise Value

Fetching Data...

Fetching Data...

Shares Outstanding

655,624,293

(16.4722)%

Pharmaxis Performance History

Community Sentiment 0 votes
↑ 0% ↓ 0%

Description

Pharmaxis Ltd engages in the research, development, and commercialization of healthcare products for the treatment of fibrotic and inflammatory diseases worldwide. The company operates through two segments, Mannitol Respiratory Business and New Drug Development. It offers Bronchitol, an inhaled dry powder for the treatment of cystic fibrosis; and Aridol, an airways inflammation test that is used to identify twitchy or hyper-responsive airways, as well as to assist in diagnosing and managing asthma. The company's product pipeline consists of oral pan-lysy... Read More

Sector: Healthcare

  • Previous Close Fetching Data...
  • Range $0.027-0.065
  • Market Cap 20.23M
  • Enterprise Value No Data
  • Avg Volume Fetching Data...
  • P/E Ratio Fetching Data...
  • Dividend Yield Fetching Data...

Industry: Drug Manufacturers - Specialty & Generic

  • ceo: Mr. Gary Jonathan Phillips BPharm, MBA
  • IPO Date: November, 09, 2003
  • Country: AU
  • Currency: AUD
  • Headquaters: Frenchs Forest, NSW
  • Employees: 70

- Revenue from each product or segment:

Product or Segment Value: % - Total Last 3Y:
news-img

- Revenue by Region

Product or Segment Value: % - Total Last 3Y:
news-img
8 New Orders
close
Theme Customizer

Customize your theme

close

Theme variation